Perfil de la empresa · Healthcare

Bio-Techne Corp

TECH · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
9 de febrero de 1989
Empleados
3100
Precio actual
$57.94
En vivo · 18 de junio de 2026
Compra razonable
≤ $35
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
27/100
Débil
Valor intrínseco · Rango en tres niveles Precio actual $57.94 En vivo · Por encima del techo optimista · crecimiento futuro sobregirado

Rango de valoración compuesto · conservador $24–$30 / razonable $31–$42 / optimista $45–$56. A $57.94, Por encima del techo optimista · crecimiento futuro sobregirado.

Al publicar $51.68 (31 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Capitalización8611,28 MUS$
Ingresos (TTM)1210,81 MUS$
EBITDA366,04 MUS$
Margen neto9,05 %
ROE5,34 %
PER (TTM)78,57
PER previsto26,95
PEG0,76
BPA0,70 US$
Rentabilidad por dividendo0,57 %
Rango de 52 semanas43,12 US$ – 71,93 US$
Precio objetivo de analistas61,69 US$
Recomendación de analistas4.1 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.